Skin toxicities associated with epidermal growth factor receptor inhibitors
about
Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysisManagement of EGFR-inhibitor associated rash: a retrospective study in 49 patientsCutaneous adverse reactions specific to epidermal growth factor receptor inhibitorsConcordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsCan knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Structural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibodyCutaneous complications of molecular targeted therapy used in oncologyMeasuring symptoms as a critical component of drug development and evaluation in hematological diseasesRandomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial.A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.Targeting the EGFR signaling pathway in cancer therapy.Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses.Immune biomarkers of anti-EGFR monoclonal antibody therapyRash rates with egfr inhibitors: meta-analysis.Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma.Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multiA Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers.Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.Modeling the transcriptional consequences of epidermal growth factor receptor ablation in Ras-initiated squamous cancer.Disseminated Mycobacterium chelonae infection in a patient receiving an epidermal growth factor receptor inhibitor for advanced head and neck cancerNanocarriers to Enhance the Accumulation of Vitamin K1 into the Skin.Topical use of olive oil preparation to prevent radiodermatitis: results of a prospective study in nasopharyngeal carcinoma patients.Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients.Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung CancerManagement of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 creamEfficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.Role of EGFR expression levels in the regulation of integrin function by EGF.Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors.Chemotherapy and skin reactions.Targeted therapies in colorectal cancer-an integrative view by PPPMPhase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.Targeting developmental pathways in children with cancer: what price success?A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis.Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy.Predicting Diagnostic Gene Biomarkers for Non-Small-Cell Lung Cancer.The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials
P2860
Q21133732-B43BBECA-B8BC-410D-9E02-F501E9CB60B9Q21195817-EEC86973-8B04-40BE-BD31-9D9E68A19A01Q26781472-05D5346B-6F10-499D-AA3E-67B34ED9D56AQ26830569-29EA3266-9423-4AD0-9AAB-D66AFD3A3B59Q26859144-0346EF92-23BB-43D5-A0FF-C9D36DF0A40AQ27727718-D8204B6F-3938-474D-B754-B52C4FE9CE22Q28070095-C44D927B-CF7E-4972-ADC9-572783FC2B86Q33705743-A741CDD6-1E8F-49B2-8F16-A23C46C9911FQ33733218-A5E1952C-0940-44C9-B1FA-0A183E8F0B05Q34180815-302F6B8F-FF6F-4713-BB22-3B62E4217279Q34246558-C6C7BCD2-5B83-4B1F-9851-B28819BB7A68Q34250187-D3CA51D0-ECC3-4863-A74C-2CC00B759B33Q34626878-861405EF-07C1-4766-BD23-D09056B1753AQ34723594-4CA26191-645C-45DA-9379-BA594BB0B4F0Q34761646-BA5B2C76-9C6A-4E8F-A5D8-AA9A3B4C302CQ34790902-1CB43FC7-0073-44B8-B225-42EB8612DB10Q34820775-FFD34A65-CA2C-4277-9960-A6FB7D2A307EQ35034768-387D90BA-EFBD-488D-92D7-8CBF3F370420Q35059625-36F7F41B-F828-410D-BD65-0F75E0DF0ACBQ35528877-4EE92CE9-8D8D-49B5-BDB6-1D1581D03A78Q35584416-9BDB54CD-BB9C-4CD8-9372-76919DDB159BQ35653271-C3ACD866-8473-4A8E-AE6F-25C0CA574218Q35668258-ACBB0F5B-B783-49B4-9606-E01FB58C36F9Q35856187-15A96EFE-5759-4228-B572-1230EE8B4C79Q36046400-00F00EF6-0F93-4D15-80F4-AF9C36F0CF22Q36078657-042C0E2D-C5FB-471D-8853-B156088A4A77Q36088496-4F1A57A4-809C-4A03-97E0-5DEB5A75DBD4Q36177683-3C93D30B-3526-42DC-9276-8121A11215DCQ36205327-8C2A2525-DBFE-49C0-8695-639F2172349DQ36348380-D79A1FA4-F838-46BB-B298-C32031F1E8A2Q36470125-21AB72DF-B98F-4204-9A5A-DFDB4A8D5120Q36641727-5575616A-C4EA-4EE5-BF5E-D5E1D86C3BABQ36646911-B0664EBD-7556-4332-B223-EF08DCB8F9FFQ36713320-43589B4F-3525-455B-A9A1-550120C7736BQ36905620-78D42403-BCB7-4C41-941E-452577BF895DQ36951089-D6969D9C-6E08-4213-9837-538ABD9F9AF3Q37138420-705DF269-2C12-464B-85D1-AFC51E12C41FQ37184578-9B5B7253-2690-4A0D-B7C4-6A95B6FD1609Q37226025-81E1A697-5580-4921-BBEA-B3549DEF99DCQ37231066-3F80A3AF-B922-440C-9D77-10B9541F0E4C
P2860
Skin toxicities associated with epidermal growth factor receptor inhibitors
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Skin toxicities associated with epidermal growth factor receptor inhibitors
@ast
Skin toxicities associated with epidermal growth factor receptor inhibitors
@en
Skin toxicities associated with epidermal growth factor receptor inhibitors
@nl
type
label
Skin toxicities associated with epidermal growth factor receptor inhibitors
@ast
Skin toxicities associated with epidermal growth factor receptor inhibitors
@en
Skin toxicities associated with epidermal growth factor receptor inhibitors
@nl
prefLabel
Skin toxicities associated with epidermal growth factor receptor inhibitors
@ast
Skin toxicities associated with epidermal growth factor receptor inhibitors
@en
Skin toxicities associated with epidermal growth factor receptor inhibitors
@nl
P3181
P1433
P1476
Skin toxicities associated with epidermal growth factor receptor inhibitors
@en
P2093
Roman Perez-Soler
Tianhong Li
P2888
P304
P3181
P356
10.1007/S11523-009-0114-0
P407
P577
2009-04-01T00:00:00Z
P5875
P6179
1000094783